Early and accurate differentiation between Alzheimer’s disease (AD) and mild cognitive impairment (MCI) is increasingly critical as new disease-modifying therapies emphasize intervention at the earliest possible stages. However, MCI often represents a heterogeneous and nonspecific prodromal phase, complicating clinical diagnosis when symptoms overlap. Recent research highlights the potential of Biomarker-Based Electrophysiology for Advanced Monitoring (BEAM) as a novel, non-invasive approach to improve diagnostic precision .
The Challenge of Distinguishing AD from MCI
MCI is commonly viewed as an intermediate stage between normal aging and dementia, but it can precede multiple neurodegenerative conditions—not only Alzheimer’s disease. Clinical assessments alone may be insufficient when cognitive presentations are ambiguous, underscoring the need for objective biomarkers that reflect underlying brain physiology.
Electrophysiological biomarkers derived from electroencephalography (EEG) and event-related potentials (ERPs) provide real-time insights into neural function and may help clarify distinctions between AD and MCI.
What Is BEAM?
Biomarker-Based Electrophysiology for Advanced Monitoring (BEAM) is a diagnostic platform that integrates:
- EEG-based electrophysiology
- Neurocognitive testing
- ERP analysis
By combining these elements, BEAM evaluates neural processing patterns associated with cognitive impairment and neurodegenerative disease, offering a scalable and non-invasive assessment tool .
Study Aims and Design
The study aimed to evaluate whether BEAM could identify distinct electrophysiological differences between patients with MCI and those with Alzheimer’s disease.
Methods Overview
A retrospective chart review was conducted on 128 patients who underwent BEAM testing:
- MCI: 96 patients
- Alzheimer’s disease: 32 patients
Multivariate linear regression analyses were performed, controlling for:
- Age at BEAM testing
- Sex
- Mini-Mental State Examination (MMSE) tertile scores
- 28–30: healthy/mild
- 25–27: moderate
- <24: severe
Key Findings: Electrophysiological Biomarkers
The analysis identified significant inter-group differences in specific EEG-derived biomarkers:
- Peak Alpha Frequency (PAF): Reduced mean values in patients with AD compared to MCI (PAF slope: −0.751, p = 0.005)
- Posterior Dominance of Alpha (PDA): Lower posterior alpha activity in AD patients (PDA slope: −1.702, p = 0.035)
Other BEAM-derived measures did not reach statistical significance, highlighting the specificity of PAF and PDA as distinguishing biomarkers .
Clinical Implications of PAF and PDA
Alpha rhythm abnormalities have long been associated with neurodegeneration. The findings suggest that:
- Decreased PAF reflects slowed neural processing in AD
- Reduced PDA indicates disruption of posterior cortical networks
These electrophysiological changes may emerge earlier in Alzheimer’s disease than overt clinical decline, supporting BEAM’s role in earlier identification of AD among patients with MCI-like symptoms.
Advancing Non-Invasive Diagnostic Tools in Dementia Care
The study demonstrates that BEAM has potential as a non-invasive clinical tool to enhance diagnostic accuracy in cognitive disorders. By identifying objective differences in brain activity, BEAM may:
- Support earlier diagnosis of Alzheimer’s disease
- Improve patient stratification in clinical trials
- Complement existing cognitive and imaging assessments
Such tools are increasingly important as precision medicine and early intervention become central to dementia care.
Conclusion
This research supports the utility of Biomarker-Based Electrophysiology for Advanced Monitoring (BEAM) in distinguishing Alzheimer’s disease from mild cognitive impairment through specific electrophysiological biomarkers, particularly PAF and PDA. BEAM represents a promising step toward more accurate, accessible, and earlier diagnosis of Alzheimer’s disease, with important implications for both clinical practice and research.
